Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

OM 8980

Known as: OM-8980 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
SummaryA 6-month double-blind study of OM-8980 and auranofin in 145 patients with rheumatoid arthritis was followed by an open… Expand
  • table I
  • figure 1
  • table II
Is this relevant?
1999
1999
Abstract This open-label, long-term, prospective study on the use of the bacterial extract OM-8980 in patients with rheumatoid… Expand
Is this relevant?
1994
1994
OM-8980 is a slow-acting antirheumatic drug (SAARD). It is a glycoprotein extract of Escherichia coli, with immunomodulatory… Expand
  • table I
  • table I
  • table II
  • figure 1
  • table III
Is this relevant?
1993
1993
Sixty patients with active RA were evaluated over 6 months in a double-blind randomized dose range multicentre study comparing… Expand
Is this relevant?
Review
1993
Review
1993
The results obtained with Subreum®, a peptide extract of E. coli, given orally, as a slow acting antirheumatic drug are… Expand
Is this relevant?
1991
1991
OM-8980 is an immunomodulating drug which has been shown in double blind placebo controlled trials to be effective in the… Expand
Is this relevant?
1990
1990
Forty patients with active rheumatoid arthritis were included in this monocentre double-blind study comparing the therapeutic… Expand
Is this relevant?
1989
1989
A new immunomodulating drug, OM-8980, was compared to placebo in a 6-month double blind multicenter trial including 107 patients… Expand
Is this relevant?
1989
1989
SummaryA total of 95 patients suffering from active rheumatoid arthritis were included in this double-blind, placebo-controlled… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
1988
1988
The therapeutic efficacy of the immunomodulator OM-8980 in rheumatoid arthritis was compared with that of auranofin, an oral gold… Expand
Is this relevant?